Core Laboratories AI Stock Analysis
Want to see CLB full AI Analyst Report?
Core Laboratories (CLB) AI Stock Analysis
Core Laboratories
(NYSE:CLB)
CLB’s score is primarily supported by improved balance-sheet leverage and positive (recently improving) free cash flow, but is held back by sharp TTM revenue contraction and margin pressure. Technicals add additional downside risk given a negative MACD and price below key moving averages, while valuation is not especially supportive with a 27.6 P/E and low dividend yield. The latest earnings call was neutral: sequential progress and longer-term wins/outlook were offset by flat near-term guidance and ongoing geopolitical disruption.
Core Laboratories Key Performance Indicators (KPIs)
Revenue By SegmentShows how different business segments contribute to overall revenue, highlighting which areas drive growth and profitability for Core Laboratories.
Reservoir Description — historically the larger, steady driver — shows a clear pullback in 2026 after peaking in 2025, while Production Enhancement staged a notable rebound in the latest quarter. That divergence suggests customers are shifting spend toward short‑cycle production work versus longer reservoir studies, increasing near‑term revenue volatility but potentially improving cash conversion and margins if intervention work is higher‑margin. Watch operator capex signals and backlog/pricing to judge whether this is a temporary cycle or a structural shift.
Core Laboratories (CLB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $417.45M
- Dividend Yield
- 0.44%
- Average Volume (3M)
- 597.77K
- Price to Earnings (P/E)
- 26.8
- Beta (1Y)
- 1.28
- Revenue Growth
- -0.15%
- EPS Growth
- -44.32%
- Country
- US
- Employees
- 3,300
- Sector
- Energy
- Sector Strength
- 65
- Industry
- Oil & Gas Equipment & Services
Core Laboratories Business Overview & Revenue Model
Company Description
Core Laboratories N.V. (CLB) is a global provider to the oil and gas sector, delivering specialized services and products for characterizing subterranean reservoirs and optimizing hydrocarbon extraction. The company's operations are distinctly segmen...
How the Company Makes Money
Core Laboratories makes money by selling specialized technical services and products to oil and gas producers, generally under service contracts and project-based work tied to customers’ exploration, appraisal, development, and production programs. I...
Core Laboratories Earnings Call Summary
The call was balanced. Core Lab reported meaningful sequential improvements in revenue, operating income, margins, product sales and EPS, along with several technology wins, a 5-year contract and expectations for stronger global activity in 2027. However, geopolitical conflicts continued to depress year-over-year service and Reservoir Description results, reduce demand for crude assay work, delay projects, constrain cash flow and create uncertainty. Fourth-quarter revenue is expected to remain relatively flat, making the overall tone neutral despite management's constructive longer-term outlook.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the fourth quarter 2026, Core Lab expects revenue to remain relatively flat sequentially; Reservoir Description revenue is projected to range from $81 million to $85 million with operating income of $5.1 million to $8.3 million, Production Enhancement revenue is estimated to range from $47.5 million to $49.5 million with operating income of $5.5 million to $6.7 million, and company revenue is projected to range from $128.5 million to $134.5 million with operating income of $10.7 million to $15.1 million, yielding operating margins of 10%, while EPS is expected to range from $0.12 to $0.20; guidance excludes gains and losses in foreign exchange and assumes an effective tax rate of 25%, 2026 G&A ex-items is expected to be approximately $43 million to $45 million, and full-year 2026 capital expenditures excluding CapEx for rebuilding the U.K. facility are expected to be in the range of $14 million to $16 million.
Core Laboratories Financial Statement Overview
Summary
Balance sheet strength is a key positive (materially improved leverage and steadily growing equity), and free cash flow is positive with an improvement in the latest period. Offsetting this, TTM revenue fell sharply and profitability compressed versus prior years, indicating weak near-term operating momentum and reduced return metrics.
Income Statement
45NeutralBalance Sheet
78PositiveCash Flow
62Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 516.74M | 526.52M | 523.85M | 509.79M | 489.74M | 470.25M |
| Gross Profit | 91.29M | 94.28M | 88.37M | 94.05M | 78.92M | 83.84M |
| EBITDA | 53.90M | 71.12M | 73.51M | 70.42M | 58.69M | 63.78M |
| Net Income | 15.56M | 29.67M | 31.40M | 36.67M | 19.45M | 19.73M |
Balance Sheet | ||||||
| Total Assets | 593.52M | 584.01M | 590.41M | 586.39M | 578.35M | 580.85M |
| Cash, Cash Equivalents and Short-Term Investments | 21.38M | 22.70M | 19.16M | 15.12M | 15.43M | 17.70M |
| Total Debt | 161.97M | 164.02M | 180.14M | 215.38M | 222.39M | 250.26M |
| Total Liabilities | 309.43M | 311.80M | 332.67M | 356.59M | 389.40M | 419.85M |
| Stockholders Equity | 277.97M | 265.99M | 251.99M | 224.81M | 184.26M | 156.45M |
Cash Flow | ||||||
| Free Cash Flow | 20.89M | 22.29M | 43.36M | 14.21M | 14.74M | 23.04M |
| Operating Cash Flow | 24.69M | 37.03M | 56.39M | 24.79M | 24.96M | 36.58M |
| Investing Cash Flow | -14.27M | -2.23M | -6.39M | -6.65M | -3.86M | -10.22M |
| Financing Cash Flow | -14.68M | -31.25M | -45.96M | -18.45M | -23.38M | -22.46M |
Core Laboratories Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLB, the sentiment is Negative. The current price of 9.11 is below the 20-day moving average (MA) of 9.71, below the 50-day MA of 10.37, and below the 200-day MA of 13.33, indicating a bearish trend. The MACD of -0.38 indicates Positive momentum. The RSI at 38.17 is Neutral, neither overbought nor oversold. The STOCH value of 23.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLB.
Core Laboratories Risk Analysis
Core Laboratories disclosed 17 risk factors in its most recent earnings report. Core Laboratories reported the most risks in the "Finance & Corporate" category.
- Finance & Corporate5
- Tech & Innovation3
- Legal & Regulatory2
- Production2
- Ability to Sell1
- Macro & Political4
Latest Risks Added
0 New RisksCore Laboratories Peers Comparison
Overall Rating
FTI76Outperform
WFRD73Outperform
BKR66Neutral
HAL66Neutral
XPRO58Neutral
CLB55Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | $25.76B | 20.45 | 38.54% | 0.30% | 7.95% | 42.53% | |
| 73Outperform | $6.27B | 15.36 | 22.51% | 1.27% | -5.65% | 0.77% | |
| 66Neutral | $49.10B | 16.87 | 14.83% | 1.86% | 3.71% | 0.14% | |
| 66Neutral | $27.94B | 14.13 | 18.46% | 2.01% | 1.53% | 58.46% | |
| Sector * | 65Neutral | $15.17B | 7.61 | 4.09% | 5.20% | 3.87% | -62.32% |
| 58Neutral | $1.51B | 1154.70 | 0.10% | ― | -4.75% | -97.74% | |
| 55Neutral | $417.45M | 26.79 | 5.73% | 0.44% | -0.15% | -44.32% |
* Energy Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CLB | Core Laboratories N.V. | 9.11 | -5.98 | -39.62% | |
| BKR | Baker Hughes Company | 49.44 | 2.30 | 4.88% | |
| FTI | TechnipFMC | 66.26 | 23.67 | 55.58% | |
| HAL | Halliburton Company | 33.78 | 7.69 | 29.47% | |
| WFRD | Weatherford International Plc | 86.45 | 16.31 | 23.25% | |
| XPRO | Expro Group Holdings N.V. | 13.51 | 0.05 | 0.37% |
Core Laboratories Corporate Events
Core Laboratories Posts Solid Q3 2026 Revenue Growth
PositiveOn October 28, 2026, Core Laboratories reported third quarter 2026 revenue of $132.1 million, up 6% sequentially but down 2% year over year, with GAAP operating income of $12.1 million and earnings per share of $0.12. On an adjusted basis, operating...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026
